Published in AIDS on February 15, 2002
Efavirenz-induced gynecomastia in a prepubertal girl with human immunodeficiency virus infection: a case report. BMC Pediatr (2013) 0.76
The man with bilateral nipple pain. Malays Fam Physician (2013) 0.75
Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa. AIDS Res Ther (2016) 0.75
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS (2002) 4.42
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis (2005) 2.07
Lower systolic blood pressure is associated with poorer survival in long-term survivors of stroke. J Hypertens (2014) 2.05
Importance of ambulatory blood pressure in hypertension management. Med J Aust (2012) 1.99
When should antiretroviral therapy for HIV be started? BMJ (2007) 1.95
Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol (2004) 1.89
Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS (2002) 1.74
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med (2006) 1.65
Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr (2005) 1.50
Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther (2005) 1.48
Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes? Med J Aust (2009) 1.45
Public funding of large-scale clinical trials in Australia. Med J Aust (2003) 1.44
The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml. AIDS (2002) 1.41
Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS (2002) 1.40
Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS (2013) 1.28
Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS (2004) 1.26
A randomised controlled trial of the effects of mindfulness practice on medical student stress levels. Med Educ (2011) 1.19
Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapy. AIDS (2005) 1.18
The acute-phase protein response to infection in edematous and nonedematous protein-energy malnutrition. Am J Clin Nutr (2002) 1.07
Transient nature of long-term nonprogression and broad virus-specific proliferative T-cell responses with sustained thymic output in HIV-1 controllers. PLoS One (2009) 1.06
Ambulatory blood pressure monitoring in Australia: 2011 consensus position statement. J Hypertens (2012) 1.06
Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence. J Clin Oncol (2002) 1.00
Identifying the health and mental health information needs of people with coronary heart disease, with and without depression. Med J Aust (2008) 0.98
Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors? AIDS (2002) 0.98
Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV cohort, 1988-2010. PLoS One (2012) 0.94
HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation. Antivir Ther (2007) 0.94
Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. J Acquir Immune Defic Syndr (2005) 0.93
Elevated plasma lipopolysaccharide is not sufficient to drive natural killer cell activation in HIV-1-infected individuals. AIDS (2009) 0.91
Reduced T(H)1/T(H)17 CD4 T-cell numbers are associated with impaired purified protein derivative-specific cytokine responses in patients with HIV-1 infection. J Allergy Clin Immunol (2011) 0.91
Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS (2002) 0.90
The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals. J Acquir Immune Defic Syndr (2009) 0.89
Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection. AIDS (2003) 0.89
Potential of surface-coil MRI for staging of esophageal cancer. AJR Am J Roentgenol (2006) 0.87
Successful treatment of acute haemorrhagic cytomegalovirus colitis with ganciclovir in an individual without overt immunocompromise. Eur J Gastroenterol Hepatol (2003) 0.87
Australians at risk: management of cardiovascular risk factors in the REACH Registry. Heart Lung Circ (2007) 0.87
Depletion of natural killer cells in the colonic lamina propria of viraemic HIV-1-infected individuals. AIDS (2007) 0.86
Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy? J Clin Oncol (2003) 0.85
The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine. Antivir Ther (2005) 0.85
Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection. AIDS (2007) 0.85
Psychosocial factors in adults with chronic kidney disease: characteristics of pilot participants in the Tasmanian Chronic Kidney Disease study. BMC Nephrol (2013) 0.83
The evolution of coreceptor tropism in HIV-infected patients interrupting suppressive antiretroviral therapy. Clin Infect Dis (2011) 0.83
Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr (2014) 0.82
Systolic blood pressure variability is an important predictor of cardiovascular outcomes in elderly hypertensive patients. J Hypertens (2014) 0.82
Coronary heart disease risk prediction by general practitioners in Victoria. Med J Aust (2004) 0.81
Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men. Br J Nutr (2009) 0.81
Clearance of hepatitis C virus RNA from serum in HIV/hepatitis C virus coinfection indicates eradication from peripheral blood mononuclear cells. AIDS (2010) 0.80
Gastro-oesophageal reflux disease--impact of guidelines on GP management. Aust Fam Physician (2008) 0.80
Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis. Med J Aust (2012) 0.80
Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy. J Interferon Cytokine Res (2008) 0.79
Short- and long-term survival in treated elderly hypertensive patients with or without diabetes: findings from the Second Australian National Blood Pressure study. Am J Hypertens (2013) 0.79
Risk factor management in survivors of stroke: a double-blind, cluster-randomized, controlled trial. Int J Stroke (2012) 0.79
True gynaecomastia, another manifestation of immune reconstitution disease? Int J STD AIDS (2002) 0.79
Home blood pressure monitoring: Australian Expert Consensus Statement. J Hypertens (2015) 0.79
The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safe. Blood (2006) 0.78
Short communication: NKG2C+ NK cells contribute to increases in CD16+CD56- cells in HIV type 1+ individuals with high plasma viral load. AIDS Res Hum Retroviruses (2012) 0.78
Tetanus vaccination with IL-2 during highly active antiretroviral therapy induces sustained and pronounced specific CD4 T-cell responses. AIDS (2004) 0.78
How cardiac patients describe the role of their doctors in smoking cessation: a qualitative study. Aust J Prim Health (2011) 0.78
New drugs. J HIV Ther (2005) 0.77
Lopinavir/ritonavir (ABT-378/r). Expert Opin Pharmacother (2002) 0.77
From research and guidelines to the consultation: five ways to improve blood pressure management in clinical practice. Med J Aust (2009) 0.77
Opportunistic protozoan diarrhoea. J HIV Ther (2002) 0.76
Rising rates of HIV infection. BMJ (2005) 0.75
A marriage of inconvenience. Med J Aust (2006) 0.75
The JNC 7 hypertension guidelines. JAMA (2003) 0.75
General practice trials: the importance of creating evidence. Med J Aust (2012) 0.75
Managing conjunctivitis in general practice: recommendations depend on health system. BMJ (2006) 0.75
A no-fault compensation scheme for serious adverse events attributed to vaccination. Med J Aust (2011) 0.75
Cardiovascular risk perception and evidence-practice gaps in Australian general practice. Med J Aust (2010) 0.75
Importance of ambulatory blood pressure in hypertension management. Med J Aust (2013) 0.75
Interpretation of screening test results: best performers have the most to learn. BMJ (2006) 0.75
Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. Med J Aust (2004) 0.75
Benefits of blood pressure lowering are seen across levels of baseline blood pressure, comorbidity and drug class. Evid Based Med (2016) 0.75
BleedScore proposal. Am J Cardiol (2007) 0.75
Blood pressure measurement. Oscillometric devices are good in routine practice. BMJ (2011) 0.75